Zobrazeno 1 - 9
of 9
pro vyhledávání: '"vesicle immunogenicity"'
Publikováno v:
Frontiers in Microbiology, Vol 12 (2021)
Bacterial membrane vesicles (MVs) are produced by both Gram-positive and Gram-negative bacteria during growth in vitro and in vivo. MVs are nanoscale vesicular structures with diameters ranging from 20 to 400 nm. MVs incorporate bacterial lipids, pro
Externí odkaz:
https://doaj.org/article/cba353de2bf14b96acdda2b4d87bc615
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Hu, Kai1 (AUTHOR), McKay, Paul F.1 (AUTHOR), Samnuan, Karnyart1 (AUTHOR), Najer, Adrian2 (AUTHOR), Blakney, Anna K.1 (AUTHOR), Che, Junyi2 (AUTHOR), O'Driscoll, Gwen2,3 (AUTHOR), Cihova, Martina2 (AUTHOR), Stevens, Molly M.2 (AUTHOR), Shattock, Robin J.1 (AUTHOR) r.shattock@imperial.ac.uk
Publikováno v:
Journal of Extracellular Vesicles. Mar2022, Vol. 11 Issue 3, p1-17. 17p.
Publikováno v:
生物医学转化, Vol 4, Iss 1, Pp 6-14-77 (2023)
Bacterial membrane vesicles (BMVs) are nanoscale vesicular structures produced by prokaryotic bacteria during their growth. The diameter of BMVs varies between 20 and 400 nm. BMVs can incorporate bacterial proteins, nucleic acids, and lipids. On the
Externí odkaz:
https://doaj.org/article/69fa6c109b5f4c8fad3b8516f62979b0
Autor:
Carly M. Bliss, Andrea J. Parsons, Raffael Nachbagauer, Jennifer R. Hamilton, Federica Cappuccini, Marta Ulaszewska, Jason P. Webber, Aled Clayton, Adrian V.S. Hill, Lynda Coughlan
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 16, Iss , Pp 108-125 (2020)
Adenoviral (Ad) vectors represent promising vaccine platforms for infectious disease. To overcome pre-existing immunity to commonly used human adenovirus serotype 5 (Ad5), vectors based on rare species or non-human Ads are being developed. However, t
Externí odkaz:
https://doaj.org/article/cd6a0c58b0e84b3aad7a70894ddac5d1
Publikováno v:
Nanomedicine; Aug2020, Vol. 15 Issue 19, p1873-1896, 24p
Publikováno v:
Science. 12/18/2015, Vol. 350 Issue 6267, p1487-1488. 2p.
Autor:
Aled Clayton, Marta Ulaszewska, Andrea J. Parsons, Lynda Coughlan, Jennifer R. Hamilton, Carly M. Bliss, Federica Cappuccini, Raffael Nachbagauer, Adrian V. S. Hill, Jason P. Webber
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 16, Iss, Pp 108-125 (2020)
Adenoviral (Ad) vectors represent promising vaccine platforms for infectious disease. To overcome pre-existing immunity to commonly used human adenovirus serotype 5 (Ad5), vectors based on rare species or non-human Ads are being developed. However, t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::438263124ab26c6b47cc0045e6be70cd
https://cronfa.swan.ac.uk/Record/cronfa54915/Download/54915__18110__4debbcee8231468bbd3eb126032dd58d.pdf
https://cronfa.swan.ac.uk/Record/cronfa54915/Download/54915__18110__4debbcee8231468bbd3eb126032dd58d.pdf
Autor:
Angela Colmone
Publikováno v:
Science. 350:1487-1487
Graft Rejection These days organ transplantation may seem like a routine procedure, but rejection of the donated organ still poses a substantial risk. Autoantibodies contribute to rejection, but how these autoantibodies are generated remains unclear.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3fecc2e93bdae6b4e089fdf311cac841
https://doi.org/10.1126/science.350.6267.1487-c
https://doi.org/10.1126/science.350.6267.1487-c